William Blair research analyst Matt Phipps was quoted in MedCity News following Bristol Myers Squibb’s acquisition of Mirati Therapeutics. Phipps weighed in on the target of the acquisition, cancer drug Krazati.
Equity Research
Matt Phipps Highlights Impact of Acquisition by Bristol Myers Squibb in MedCity News
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
-
-
Monthly Macro with Richard de Chazal: April’s Economic Rollercoaster
William Blair macro analyst Richard de Chazal breaks down a wild month of macroeconomic news, focusing on the impact of President Trump’s tariff policies on the global economy, equity and bond markets, consumer confidence, and corporate inventory strategies.
-
Navigating the AI Boom: Applications and Monetization
The number of GenAI companies emerging continues to grow, and how these apps are utilized differs between consumers and enterprises. In our third installment of Navigating the AI Boom, we explore the primary ways to monetize GenAI and how it may impact the software industry.